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Abstract
Enterococci are a leading cause of healthcare-associated infections world-wide and display increasing levels of resistance to many of the commonly used antimicrobials, making treatment of their infections challenging. Combinations of antibiotics are occasionally employed to treat serious infections allowing for the possibility of synergistic killing.
The aim of this study was to evaluate the effects of different antibacterial combinations against enterococcal isolates using an in vitro approach and in vivo Galleria mellonella infection model.
Five Enterococcus faecalis and three E. faecium strains were screened by paired combinations of rifampicin, tigecycline, linezolid, or vancomycin, using a chequerboard dilution method. Antibacterial combinations that displayed synergy were selected for in vivo testing The addition of rifampicin to anti-enterococcal treatment regimens warrants further investigation and may prove useful in the treatment of enterococcal infections, whilst prolonging the clinically useful life of currently active antibiotics.
Introduction
Enterococci cause a spectrum of infections from uncomplicated urinary tract infection to lifethreatening endocardial and device-related infections. These pathogens are intrinsically resistant to a number of commonly used antimicrobials and have a remarkable ability to acquire new resistance mechanisms. This situation has fuelled global concern over future treatment options for serious enterococcal infections caused by multi-drug resistant strains. Antibacterial agents commonly utilised or recently developed for the treatment of enterococcal infections include vancomycin, linezolid, daptomycin, telavancin and dalbavancin.
Tigecycline has been suggested as an alternative therapy, but with the exception of intraabdominal infections, a current lack of clinical data has impeded greater use [1] . As resistance to many of these antibacterials increases, including tigecycline [2] , therapeutic options become progressively more limited and the need for strategies to protect against further loss of activity becomes paramount.
Prescribing antibacterial combinations is established clinical practice for treatment of serious infections. There are several potential advantages to combined therapy: enhanced killing effect and the possibility of synergy, a reduction in the concentration of individual agents required (reduced toxicity, selection pressure), and of vital importance, the ability to protect against development of resistance. Daptomycin is, for example, recommended as part of a combined therapy for serious infections [3, 4] . Rifampicin is rapidly bactericidal against many Gram-positive bacteria and displays good tissue penetration, but the rapid development of resistance precludes its use as monotherapy [4] leading to this old agent often being considered specifically for use in combination therapy [5, 6] .
The aim of this study was to describe the killing effect of different antibacterial combinations against clinical enterococcal isolates using standard methods and the in vivo G. mellonella infection model.
Material and methods

Bacterial isolates and growth conditions
Eight enterococcal isolates were studied: including three vancomycin sensitive strains; E. faecalis ATCC 29212, E. faecalis clinical isolates E019 and E045; as well as four vancomycin resistant strains; E. faecalis ATCC 51299, E. faecium ATCC 51559, E. faecium clinical isolates E022, E039; and one tigecycline resistant E. faecalis UW6940 (supplied by Dr Werner) ( Table   1 ).
Preparation of antibiotics
Vancomycin and rifampicin were purchased from Sigma-Aldrich (Sigma-Aldrich, Dorset, UK).
Linezolid and tigecycline were gifted from Pfizer (Pfizer Ltd, Surrey, UK). Antibiotic stocks of 10,000 mg/L (except linezolid 1,000 mg/L) were freshly prepared using distilled water each day (linezolid and tigecycline) or stored at -20°C for a maximum of one week (vancomycin and rifampicin).
2.3Antibiotic susceptibility testing
The minimum inhibitory concentration (MIC) of antibiotics was determined by the broth microdilution method described by the British Society for Antimicrobial Chemotherapy (BSAC) for each of the eight isolates [7] . E. faecalis ATCC 29212 was included as a control strain in each experiment; all results were within guideline limits. MICs were performed in duplicate and repeated on two further occasions.
Antibacterial combination assays
Standard chequerboard assays were performed in 96-well microtitre plates with doubling dilutions of each antibiotic prepared in Muller Hinton broth. The final sub-MIC ranges used for vancomycin, rifampicin, tigecycline and linezolid were 0.12-1024 mg/L, 0.12-32 mg/L, 0.007-4 mg/L and 0.12-8 mg/L, respectively. An equal volume of standardised bacterial suspension 5x10 5 CFU/ml was added before plates were incubated at 37°C in air for 24 h. Fractional inhibitory concentrations (FICs) were calculated as the MIC of drug A or B in combination divided by the MIC of drug A or B alone, respectively, and the FIC index (FICI) was obtained by adding the two FIC values. The drug combination that consistently generated the lowest FICI after repeating the experiment in duplicate on two further occasions was used to categorise results as follows: FICIs of <0.5 were interpreted as synergistic, those >0.5 but <4 were considered as no interaction, and those above >4 were interpreted as antagonistic [8] .
Combinations demonstrated to be synergistic were assessed using the G. mellonella infection model.
G. mellonella infection model
G. mellonella wax moth larvae (Livefood UK Ltd) in their final instar stage of development were stored at room temperature in the dark and used within one week of delivery. Healthy larvae, without grey markings and of a similar weight (200-300 mg), were selected and split into experimental groups of 15 [9] . Bacterial suspensions of each isolate were prepared based on a pre-optimised dose (1x10 6 -5x10 6 CFU/larva) which caused >80% larvae deaths at 72 h postinfection (Supplemental Data Fig. 1 ).
After sterilisation of the inoculation site with 70% (v/v) ethanol, the last right proleg was used to deliver 10 µl of bacterial suspension (recorded in Fig. 1 ) into the hemocoel (primary body cavity) using a 1/2 inch, 30 gauge needle (BD precisionglide® syringe needle, Sigma) attached to a 50 µl Hamilton syringe (1705 TLL, Jaytee Biosciences, UK). Antimicrobial drugs (used at 1xMIC as monotherapy or between 1/4xMIC and 1/16xMIC for antibacterial combinations) were delivered into the hemocoel via a 10 µl injection into the last left proleg (n=15). The larvae were incubated in vented plastic petri dishes at 37°C in air and deaths were scored through observation of melanisation and failure of larvae to move in response to touch at time points 12, 24, 48, 72 and 96 h. Appropriate uninfected and vehicle controls were included for each experiment.
Pooled data from three independent experiments, using G. mellonella larvae obtained from different batches, was assessed using the Kaplan-Meier method and treatment groups were compared using the logrank (Mantel-Cox) test (GraphPad Prism ® 6). P values <0.05 were considered statistically significant.
Results
Assessing the in vitro antimicrobial sensitivities of eight enterococcal isolates using the chequerboard dilution method
Results of susceptibility testing are shown in Table 1 . No antimicrobial combination showed an antagonistic effect against any of the strains evaluated. Out of the six antimicrobial combinations, tested against eight strains, synergy was seen in six cases, but in each case it was a rifampicin-containing combination. Synergy was demonstrated against all vancomycin resistant enterococci by at least one rifampicin containing antibacterial combination; all E. faecium isolates and one E. faecalis isolate (Tables 1 and 2).
Antimicrobial treatment of infected G. mellonella larvae
Dose-dependent killing of G. mellonella was achieved when larvae were infected with 1x10 6 , 3x10 6 or 5x10 6 CFU/larva of each isolate. E. faecalis ATCC 51299 was highly virulent at all three doses tested, whilst E. faecium ATCC 51559, E. faecium E022 and E. faecium E039 were less virulent in the G. mellonella model (Supplemental Data Fig. 1 ).
Treatment of infected larvae with an antibacterial combination of sub-MIC agents consistently led to an increased level of survival (20-73% larvae survival at 96 h with a median value of 57%) compared to those treated with a higher concentration of a single agent (7-53% survival with a median value of 13%) ( Fig. 1) . A statistically significant greater level of survival was observed with four of the six combinations tested compared to the untreated control group (Fig. 1a, c , e, f), whilst only two vancomycin monotherapies administered at 1xMIC significantly improved survival of the G. mellonella compared to the control group ( Fig. 1c p=0.003, 1e p=0.0159). Furthermore, the combination of rifampicin with tigecycline was statistically superior to tigecycline alone (13% larval survival when treated with tigecycline for infection with strain E039 versus 60% larval survival when treated with the antimicrobial combination; p=0.0237) (Fig. 1f ).
Discussion
Antibacterial combination are often utilised during treatment of serious infections but the superiority of one antibiotic combination over another for the treatment of enterococcal infections remains unproven. In this study, it was demonstrated that antimicrobial combinations including rifampicin can be synergistic against enterococci but this is not a consistent finding among enterococci.
Though traditionally used in the investigation of antibacterial combinations for synergistic activity, chequerboard assays have reproducibility issues and may not adequately reflect activity in vivo. The G. mellonella in vivo infection model however, shares some basic immunity characteristics with mammals, including the deployment of proteolytic cascades (clotting and melanisation) following pathogen recognition [10] . An additional advantage and in contrast to mammalian models, G. mellonella can be inexpensively sourced and is not subject to animal research legislature [11] .
In this study the larval model corroborated the in vitro data; treatment with antibacterial combinations that were synergistic in vitro improved the survival rate of larvae against those treated with a single agent. All combinations where synergy was detected were performed with concentrations of antibacterial below the MIC (1/4-1/16 th x MIC) and contained rifampicin; rifampicin with either vancomycin or tigecycline being the most effective combinations. Of the five vancomycin or tigecycline combinations trialled, a statistically greater proportion of the larvae treated by combination therapy survived in four of the assays compared to the wax moths which were either untreated or received only one antibiotic.
Rifampicin is effective against a range of Gram positive pathogens, but the rapid development of resistance necessitates that it be used in combination with another agent. Several studies have highlighted the synergistic activity of rifampicin with others agents [6, 12] , indeed rifampicin based combinations, including vancomycin, are recommended for the treatment of staphylococcal endocarditis [3] . Combinations incorporating rifampicin are not, however, in routine use for treatment of enterococcal infections.
The classic combination of a cell wall active agent (such as vancomycin or a beta-lactam) plus an aminoglycoside results in a synergistic effect against enterococci [13] . High-level aminoglycoside resistance has however, led to a reconsideration of this standard treatment (gentamicin and ampicillin) resulting, in some instances, to the recommendation of an unusual double beta-lactam combination (ampicillin plus ceftriaxone) [14, 15] . In addition, the continual rise of vancomycin resistance has limited the value of this agent in the classic treatment and, as a consequence, excluded it in many instances from combination therapy studies. Yet a vancomycin-based combination has shown efficacy against resistant enterococci [16] . In this study, a vancomycin plus rifampicin combination improved the survival rate of G. mellonella larvae infected with selected rifampicin and/or vancomycin resistant enterococcal strains.
Typically, the interaction of tigecycline with other agents results in indifference or occasionally antagonism, an exception being with rifampicin [17] . High rates of in vitro synergism have been described for tigecycline plus rifampicin against E. faecalis and E. faecium isolates using the chequerboard dilution method [5, 18] . More recently, Silvestri et al. (2012) tested tigecycline plus rifampicin combinations in an animal model of surgical wound infections and reported good activity against enterococcal isolates [19] supporting the observations reported here with the wax moth infection model.
The failure to assess any reduction in susceptibility to agents during treatment was a limitation of the current study since the rapid development of resistance against rifampicin in particular will always remain a concern and the observations of Holmberg and Rasmussen (2014) indicate that combined therapy might not be sufficient to prevent this from developing [20] .
In conclusion, the study has revealed the efficacy of rifampicin-based combination therapies against some highly-resistant enterococci and further investigation in vivo with additional clinically relevant strains is warranted. Antibiotics; VAN -vancomycin, RIF -rifampicin, LZD -linezolid, TGC -tigecycline. Fig. 1 . Effect of inoculum dose on G. mellonella larva survival. Larvae were inoculated with three bacterial concentrations (1x10 6 CFU/larva, 3x10 6 CFU/larva and 5x10 6 CFU/larva in MH broth) of (a) E. faecalis ATCC 51299, (b) E. faecium ATCC 51559, (c) E. faecium E022 and (d) E. faecium E039 and deaths recorded at 12, 24, 48 and 72 h to assess lethal doses. Experiments were performed three times using different batches of fifteen G. mellonella and the average larvae death at each time point were determined (n=45).
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